BridgeBio Oncology Therapeutics, Inc. BBOT
2.20 USD -0.10 (-4.35%)
At closeNov 10, 2026, 4:00 PM EST
2.30 +0.10 +4.55%
After hours · Nov 10, 4:00 PM ET
2.19 Day range 2.34
1.98 52-week range 14.87
- YTD
- -82.43%
- 1 year
- -82.66%
News
benzinga.com BridgeBio Oncology Q3 EPS $(0.43) Beats $(0.69) Estimate BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.69) by 37.68 percent. This is a 58.25 percent increase over losses of…
globenewswire.com BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients BBO-11818 and BBO-10203 combination cohorts…
benzinga.com Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13 Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.- benzinga.com Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16 Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.